CDKN2A and cancer: While the amplification of oncogenes (such as EGFR, c-ERBB2, c-MYC, and c-MET) is increasingly driving decision-making for precise cancer treatments, clinical applications of SCND of tumor suppressor genes, including CDKN2A, are still rare owing to the lack of a feasible detection assay.